Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
22
SOLTF Quote, Financials, Valuation and Earnings
Last price:
$5.08
Seasonality move
:
7.2%
Day range:
$5.08 - $5.08
52-week range:
$5.00 - $7.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.37x
P/B ratio:
1.03x
Volume:
--
Avg. volume:
340
1-year change:
-17.58%
Market cap:
$459.3M
Revenue:
$190.3M
EPS (TTM):
-$0.46
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
AMGXF
AnGes, Inc.
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$7.8B | -- | 3.82% | -- | $17.93 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.08 | -- | $459.3M | -- | $0.00 | 0% | 2.37x |
|
AMGXF
AnGes, Inc.
|
$0.36 | -- | $139.1M | -- | $0.00 | 0% | 21.61x |
|
HLOSF
Healios KK
|
$1.93 | -- | $222.8M | -- | $0.00 | 0% | 303.04x |
|
PPTDF
PeptiDream Inc.
|
$11.98 | -- | $1.5B | 13.79x | $0.00 | 0% | 12.90x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$15.58 | $17.93 | $49.2B | 197.72x | $0.32 | 4.24% | 1.68x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SOLTF
Nxera Pharma Co., Ltd.
|
49.02% | 1.721 | 73.82% | 2.21x |
|
AMGXF
AnGes, Inc.
|
3.92% | 0.348 | 0.83% | 1.55x |
|
HLOSF
Healios KK
|
47.23% | -1.205 | 3.71% | 1.23x |
|
PPTDF
PeptiDream Inc.
|
25.86% | 0.045 | 8.66% | 4.05x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
39.45% | -0.563 | 68.02% | 0.64x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SOLTF
Nxera Pharma Co., Ltd.
|
$27.7M | -$23.7M | -4.62% | -9.2% | -51.66% | -$20.9M |
|
AMGXF
AnGes, Inc.
|
$669.9K | -$7.7M | -326.92% | -349.76% | -494.08% | -- |
|
HLOSF
Healios KK
|
-$637.4K | -$5.2M | -86.08% | -194.37% | -4022.21% | -$5.3M |
|
PPTDF
PeptiDream Inc.
|
$11.3M | -$9.7M | -7.71% | -10.42% | -33.1% | -$12.5M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$3.6B | $763.2M | 0.33% | 0.55% | 10.11% | $2B |
Nxera Pharma Co., Ltd. vs. Competitors
-
Which has Higher Returns SOLTF or AMGXF?
AnGes, Inc. has a net margin of -24.76% compared to Nxera Pharma Co., Ltd.'s net margin of -312.66%. Nxera Pharma Co., Ltd.'s return on equity of -9.2% beat AnGes, Inc.'s return on equity of -349.76%.
Company Gross Margin Earnings Per Share Invested Capital SOLTFNxera Pharma Co., Ltd.60.42% -$0.13 $872.1M AMGXFAnGes, Inc.42.74% -$0.01 $29.4M -
What do Analysts Say About SOLTF or AMGXF?
Nxera Pharma Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand AnGes, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Nxera Pharma Co., Ltd. has higher upside potential than AnGes, Inc., analysts believe Nxera Pharma Co., Ltd. is more attractive than AnGes, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SOLTFNxera Pharma Co., Ltd.0 0 0 AMGXFAnGes, Inc.0 0 0 -
Is SOLTF or AMGXF More Risky?
Nxera Pharma Co., Ltd. has a beta of 0.029, which suggesting that the stock is 97.149% less volatile than S&P 500. In comparison AnGes, Inc. has a beta of 0.060, suggesting its less volatile than the S&P 500 by 94.03%.
-
Which is a Better Dividend Stock SOLTF or AMGXF?
Nxera Pharma Co., Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AnGes, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nxera Pharma Co., Ltd. pays -- of its earnings as a dividend. AnGes, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SOLTF or AMGXF?
Nxera Pharma Co., Ltd. quarterly revenues are $45.8M, which are larger than AnGes, Inc. quarterly revenues of $1.6M. Nxera Pharma Co., Ltd.'s net income of -$11.3M is lower than AnGes, Inc.'s net income of -$4.9M. Notably, Nxera Pharma Co., Ltd.'s price-to-earnings ratio is -- while AnGes, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma Co., Ltd. is 2.37x versus 21.61x for AnGes, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOLTFNxera Pharma Co., Ltd.2.37x -- $45.8M -$11.3M AMGXFAnGes, Inc.21.61x -- $1.6M -$4.9M
-
Which has Higher Returns SOLTF or HLOSF?
Healios KK has a net margin of -24.76% compared to Nxera Pharma Co., Ltd.'s net margin of -9751.87%. Nxera Pharma Co., Ltd.'s return on equity of -9.2% beat Healios KK's return on equity of -194.37%.
Company Gross Margin Earnings Per Share Invested Capital SOLTFNxera Pharma Co., Ltd.60.42% -$0.13 $872.1M HLOSFHealios KK-494.88% $0.03 $37.8M -
What do Analysts Say About SOLTF or HLOSF?
Nxera Pharma Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Nxera Pharma Co., Ltd. has higher upside potential than Healios KK, analysts believe Nxera Pharma Co., Ltd. is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings SOLTFNxera Pharma Co., Ltd.0 0 0 HLOSFHealios KK0 0 0 -
Is SOLTF or HLOSF More Risky?
Nxera Pharma Co., Ltd. has a beta of 0.029, which suggesting that the stock is 97.149% less volatile than S&P 500. In comparison Healios KK has a beta of 0.210, suggesting its less volatile than the S&P 500 by 78.954%.
-
Which is a Better Dividend Stock SOLTF or HLOSF?
Nxera Pharma Co., Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nxera Pharma Co., Ltd. pays -- of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SOLTF or HLOSF?
Nxera Pharma Co., Ltd. quarterly revenues are $45.8M, which are larger than Healios KK quarterly revenues of $128.8K. Nxera Pharma Co., Ltd.'s net income of -$11.3M is lower than Healios KK's net income of $3.8M. Notably, Nxera Pharma Co., Ltd.'s price-to-earnings ratio is -- while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma Co., Ltd. is 2.37x versus 303.04x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOLTFNxera Pharma Co., Ltd.2.37x -- $45.8M -$11.3M HLOSFHealios KK303.04x -- $128.8K $3.8M
-
Which has Higher Returns SOLTF or PPTDF?
PeptiDream Inc. has a net margin of -24.76% compared to Nxera Pharma Co., Ltd.'s net margin of -25.38%. Nxera Pharma Co., Ltd.'s return on equity of -9.2% beat PeptiDream Inc.'s return on equity of -10.42%.
Company Gross Margin Earnings Per Share Invested Capital SOLTFNxera Pharma Co., Ltd.60.42% -$0.13 $872.1M PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M -
What do Analysts Say About SOLTF or PPTDF?
Nxera Pharma Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Nxera Pharma Co., Ltd. has higher upside potential than PeptiDream Inc., analysts believe Nxera Pharma Co., Ltd. is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings SOLTFNxera Pharma Co., Ltd.0 0 0 PPTDFPeptiDream Inc.0 0 0 -
Is SOLTF or PPTDF More Risky?
Nxera Pharma Co., Ltd. has a beta of 0.029, which suggesting that the stock is 97.149% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.146%.
-
Which is a Better Dividend Stock SOLTF or PPTDF?
Nxera Pharma Co., Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nxera Pharma Co., Ltd. pays -- of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SOLTF or PPTDF?
Nxera Pharma Co., Ltd. quarterly revenues are $45.8M, which are larger than PeptiDream Inc. quarterly revenues of $29.3M. Nxera Pharma Co., Ltd.'s net income of -$11.3M is lower than PeptiDream Inc.'s net income of -$7.4M. Notably, Nxera Pharma Co., Ltd.'s price-to-earnings ratio is -- while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma Co., Ltd. is 2.37x versus 12.90x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOLTFNxera Pharma Co., Ltd.2.37x -- $45.8M -$11.3M PPTDFPeptiDream Inc.12.90x 13.79x $29.3M -$7.4M
-
Which has Higher Returns SOLTF or STMM?
Stemcell Holdings, Inc. has a net margin of -24.76% compared to Nxera Pharma Co., Ltd.'s net margin of --. Nxera Pharma Co., Ltd.'s return on equity of -9.2% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SOLTFNxera Pharma Co., Ltd.60.42% -$0.13 $872.1M STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About SOLTF or STMM?
Nxera Pharma Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Nxera Pharma Co., Ltd. has higher upside potential than Stemcell Holdings, Inc., analysts believe Nxera Pharma Co., Ltd. is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SOLTFNxera Pharma Co., Ltd.0 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is SOLTF or STMM More Risky?
Nxera Pharma Co., Ltd. has a beta of 0.029, which suggesting that the stock is 97.149% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SOLTF or STMM?
Nxera Pharma Co., Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nxera Pharma Co., Ltd. pays -- of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SOLTF or STMM?
Nxera Pharma Co., Ltd. quarterly revenues are $45.8M, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. Nxera Pharma Co., Ltd.'s net income of -$11.3M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, Nxera Pharma Co., Ltd.'s price-to-earnings ratio is -- while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma Co., Ltd. is 2.37x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOLTFNxera Pharma Co., Ltd.2.37x -- $45.8M -$11.3M STMMStemcell Holdings, Inc.0.17x -- -- --
-
Which has Higher Returns SOLTF or TAK?
Takeda Pharmaceutical Co., Ltd. has a net margin of -24.76% compared to Nxera Pharma Co., Ltd.'s net margin of -1.05%. Nxera Pharma Co., Ltd.'s return on equity of -9.2% beat Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55%.
Company Gross Margin Earnings Per Share Invested Capital SOLTFNxera Pharma Co., Ltd.60.42% -$0.13 $872.1M TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B -
What do Analysts Say About SOLTF or TAK?
Nxera Pharma Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical Co., Ltd. has an analysts' consensus of $17.93 which suggests that it could grow by 14.94%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SOLTFNxera Pharma Co., Ltd.0 0 0 TAKTakeda Pharmaceutical Co., Ltd.3 0 0 -
Is SOLTF or TAK More Risky?
Nxera Pharma Co., Ltd. has a beta of 0.029, which suggesting that the stock is 97.149% less volatile than S&P 500. In comparison Takeda Pharmaceutical Co., Ltd. has a beta of 0.032, suggesting its less volatile than the S&P 500 by 96.811%.
-
Which is a Better Dividend Stock SOLTF or TAK?
Nxera Pharma Co., Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Takeda Pharmaceutical Co., Ltd. offers a yield of 4.24% to investors and pays a quarterly dividend of $0.32 per share. Nxera Pharma Co., Ltd. pays -- of its earnings as a dividend. Takeda Pharmaceutical Co., Ltd. pays out 242.25% of its earnings as a dividend.
-
Which has Better Financial Ratios SOLTF or TAK?
Nxera Pharma Co., Ltd. quarterly revenues are $45.8M, which are smaller than Takeda Pharmaceutical Co., Ltd. quarterly revenues of $7.5B. Nxera Pharma Co., Ltd.'s net income of -$11.3M is higher than Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M. Notably, Nxera Pharma Co., Ltd.'s price-to-earnings ratio is -- while Takeda Pharmaceutical Co., Ltd.'s PE ratio is 197.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nxera Pharma Co., Ltd. is 2.37x versus 1.68x for Takeda Pharmaceutical Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SOLTFNxera Pharma Co., Ltd.2.37x -- $45.8M -$11.3M TAKTakeda Pharmaceutical Co., Ltd.1.68x 197.72x $7.5B -$79.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
